HIV clinics are halting enrolment of new patients as funding stalls, MSF warnsBMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b2966 (Published 20 July 2009) Cite this as: BMJ 2009;339:b2966
- Bob Roehr
- 1Washington, DC
The international medical charity Médecins Sans Frontières (MSF) is calling for better and cheaper first line and second line treatments for HIV in the developing world, in a new report released on 20 July at the opening of the International AIDS Society meeting in Cape Town.
MSF says that a first line treatment regimen should be based on tenofovir rather than stavudine, an older, less potent drug that is more susceptible to the emergence of viral resistance and carries potential side effects of lipodystrophy and peripheral neuropathy. The World Health Organization has recommended use of tenofovir since 2006.
A generic tenofovir based regimen costs two to three times more than one based on stavudine, but that price should fall as the volume of purchases rises. Also, the more potent regimen would delay development of viral resistance, thus deferring a switch to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial